High Court of Delhi

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd.

07.10.2015

Intellectual Property Rights

Delhi High Court rules in favour of Merck for its diabetes drug

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant

Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : Glenmark merck patent diabetes

Share :